Mon Sep 09 14:10:00 UTC 2024: ## Novo Nordisk Continues Share Repurchase Program, Acquiring 13.3 Million Shares

**Bagsværd, Denmark – September 9, 2024** – Novo Nordisk, the leading global healthcare company, has continued its share repurchase program, acquiring an additional 13,351,944 B shares since February 6th, 2024. This brings the total number of shares repurchased under the program to 12,023,313 B shares, at an average price of DKK 880.98 per share, for a total transaction value of DKK 10,592,256,521.

The company initiated the program on February 6th, 2024, with the goal of repurchasing up to DKK 20 billion worth of B shares over a 12-month period. The latest phase of the program, initiated on August 7th, 2024, will see the repurchase of B shares for an amount up to DKK 2.4 billion until November 4th, 2024.

Novo Nordisk currently owns a total of 13,351,944 B shares as treasury shares, representing 0.3% of the share capital. The company’s total A and B shares, including treasury shares, amount to 4,465,000,000.

“We are committed to maximizing shareholder value,” said [Insert relevant company spokesperson name], [Insert spokesperson’s position] at Novo Nordisk. “This share repurchase program is part of our strategy to allocate capital effectively and demonstrate our confidence in the company’s long-term prospects.”

This news follows a period of strong performance for Novo Nordisk, driven by the success of its diabetes and obesity treatments. The company is expected to continue its focus on scientific breakthroughs, expanding access to its medicines, and working to prevent and ultimately cure disease.

For more information on Novo Nordisk, please visit novonordisk.com.

Read More